Beclomethasone
Mostrando 13-24 de 68 artigos, teses e dissertações.
-
13. Response of patients receiving high dose beclomethasone dipropionate
Costello, J. F. and Clark, T. J. H. (1974).Thorax, 29, 571-573. Response of patients receiving high dose beclomethasone dipropionate. Beclomethasone dipropionate was inhaled by 16 patients with asthma in a dose of 1 mg daily for periods up to 24 weeks. No evidence of adrenal suppression was found in these patients as judged by basal cortisol levels. A furthe
-
14. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma.
This study was designed to compare the efficacy and safety of a new inhaled corticosteroid, fluticasone propionate at a total daily dose of 200 micrograms, with beclomethasone dipropionate 400 micrograms/day in childhood asthma. A total of 398 asthmatic children (aged 4-19 years) were randomised to receive either fluticasone propionate 200 micrograms daily o
-
15. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation?
BACKGROUND--It is common for inhaled steroids to be delivered through a large volume spacer device. Comparatively little is known about how this practice affects the dose of drug received by patients compared with drug delivered directly from a metered dose inhaler. METHODS--The amount of beclomethasone dipropionate, contained in particles of various size, a
-
16. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma.
BACKGROUND--Fluticasone propionate is a new inhaled corticosteroid with a 2:1 efficacy ratio compared with beclomethasone dipropionate with regard to lung function and symptom scores, without increased systemic activity. The aim of this study was to investigate whether this was also the case for bronchial hyperresponsiveness, assessed by both a direct (hista
-
17. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function.
BACKGROUND: The systemic effects of the inhaled corticosteroid beclomethasone dipropionate are reduced if the drug is inhaled through a large volume spacer. Use of spacers may therefore permit higher doses to be given without causing hypothalamo-pituitary-adrenal suppression. METHODS: Randomised, double blind, double dummy, parallel group study was carried o
-
18. Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records
Objective To determine whether inhaled budesonide and beclomethasone are equipotent in the treatment of asthma in primary care.
British Medical Journal.
-
19. Comparison of inhaled beclomethasone dipropionate 1000 micrograms twice daily and oral prednisone 10 mg once daily in asthmatic patients.
BACKGROUND--Glucocorticosteroids are widely used as drugs of first choice in the treatment of moderate to severe asthma. The effects of inhaled steroids in high doses have been compared with oral prednisone in asthmatic patients in a double blind crossover study. METHODS--The trial consisted of a two week run in period followed by two four week treatment per
-
20. Effect of prednisone and beclomethasone dipropionate on airway responsiveness in asthma: a comparative study.
To examine the effect of corticosteroids on bronchial hyperresponsiveness, a randomised, double dummy, single blind crossover study was performed in 18 subjects with chronic asthma, comparing the effect of three weeks' treatment with inhaled beclomethasone dipropionate, 1200 micrograms daily, and oral prednisone 12.5 mg daily. The 12 week study began with a
-
21. Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate.
Short-term lower leg growth was investigated with twice weekly knemometry measurements in 19 schoolchildren with mild asthma during treatment with daily doses of 200 micrograms fluticasone propionate, 400 micrograms, and 800 micrograms beclomethasone dipropionate from a dry powder inhaler. The design was a randomised, double blind, crossover trial. After a r
-
22. Particle size of beclomethasone dipropionate produced by two nebulisers and two spacing devices.
An impactor method was used to assess the amount of beclomethasone dipropionate in particles less than 5 microns produced by two nebulisers (Pari Inhalierboy, Medix Traveller compressor with cirrhus nebuliser chamber) and two spacer devices (Volumatic and Nebuhaler). After nebulisation of 3 ml (150 micrograms) beclomethasone dipropionate the amount of drug i
-
23. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler.
BACKGROUND: High doses of inhaled corticosteroids are absorbed systemically and may cause long term side effects. As rinsing the mouth out after use and inhaling through a spacing device may reduce systemic absorption this has been further investigated. METHODS: Three crossover studies were carried out to assess the effect of budesonide given by dry powder i
-
24. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group.
BACKGROUND--High dose inhaled glucocorticosteroids are increasingly used in the management of patients with moderate to severe asthma. Although effective, they may cause systemic side effects. Fluticasone propionate is a topically active inhaled glucocorticosteroid which has few systemic effects at high doses. METHODS--Fluticasone propionate, 1.5 mg per day,